CJC-1295 vs Sermorelin: GHRH Analog Research Comparison

CJC-1295 and sermorelin are both growth-hormone-releasing-hormone (GHRH) analogs studied for pituitary GH-axis modulation. They share the same receptor and downstream cascade but differ markedly in half-life, dosing cadence, and how faithfully they preserve native GH pulsatility. This comparison summarises the published literature relevant to laboratory research.

At-a-glance comparison

| Attribute | CJC-1295 | Sermorelin | |---|---|---| | Class | GHRH analog | GHRH analog (GHRH 1-29) | | Sequence basis | Tetra-substituted GRF(1-29) | Native human GRF(1-29) | | Variants | With DAC (~8 day) and without DAC (~30 min) | Single form (~10-20 min) | | Pulsatility preservation | High (no-DAC); Low (DAC, tonic elevation) | Very high | | Typical research dosing | 100 mcg (no-DAC) or 1-2 mg weekly (DAC) | 200-500 mcg per administration | | Receptor desensitisation risk | Higher with DAC tonic exposure | Low |

Mechanism

Both bind the pituitary GHRH receptor on somatotrophs to trigger endogenous GH release. Because both work upstream of negative feedback (somatostatin, IGF-1), neither overrides the regulatory loop — distinguishing them from direct GH administration.

Pharmacokinetics

Sermorelin shares the ~10-20 minute plasma half-life of native GHRH(1-29), making its profile closest to physiological pulses. CJC-1295 without DAC extends this to ~30 minutes via tetra-substitution that resists DPP-IV cleavage. CJC-1295 with DAC covalently binds serum albumin and persists ~8 days, producing sustained (tonic) GHRH-receptor occupancy rather than discrete pulses.

Pulsatility — the central trade-off

The published research literature consistently notes that pulsatile GH exposure (sermorelin, CJC-1295 no-DAC) more closely mimics native physiology, while tonic exposure (CJC-1295 DAC) produces sustained IGF-1 elevation at the cost of pulse shape. Researchers selecting a model should match the molecule to the question: pulsatility studies favour sermorelin; steady-state IGF-1 elevation studies favour DAC.

Published research highlights

• Sermorelin has the longest clinical research history of any GHRH analog, with published data spanning pediatric growth, adult GH-deficiency diagnostics, and geroscience pilots.
• CJC-1295 (no-DAC) studies typically pair it with a ghrelin-receptor agonist (e.g. ipamorelin) to amplify pulse amplitude additively.
• CJC-1295 DAC studies report sustained IGF-1 elevation across the dosing interval with single weekly administration.

Stacking and combination research

Both molecules are commonly studied alongside ghrelin-receptor agonists (ipamorelin, GHRP-2, GHRP-6, hexarelin). The GHRH + GHRP combination produces a larger GH pulse than either alone because the two receptors converge on the same somatotroph through distinct signalling cascades.

Safety and selectivity in published research

Both peptides are reported as selective for the GHRH pathway with minimal prolactin or cortisol release at studied doses. The longer tonic exposure of CJC-1295 DAC has been associated with greater receptor desensitisation risk in some preclinical models — an active area of published discussion.

Frequently asked research questions

Which is closer to native physiology? Sermorelin and CJC-1295 without DAC both preserve pulsatility; sermorelin is closer in half-life to native GHRH(1-29).

Why do researchers add DAC? DAC (drug-affinity complex) covalently tethers the peptide to serum albumin, extending half-life from minutes to days. The trade-off is loss of pulsatile signalling.

Are they interchangeable? No. Despite sharing a receptor, half-life and pulsatility differences mean they answer different research questions.

Related research

• HGH vs Tesamorelin research comparison
• CJC-1295 vs Ipamorelin research comparison
• HGH vs IGF-1 LR3 research comparison